CBX7 is upregulated in follicular lymphoma [34]; Cbx7 promotes lymphoma‐ and leukemogenesis; transplanting Cbx7‐OE HSCs results in lymphoma [34] and leukemia [5, 35] development in recipient mice, whereas Cbx7‐KO mice completely abolish the lymphoma incidents [17]; CBX7 is suggested to have a tumor suppressor role CML; CBX7 expression is low in CML, which increases during TKI treatment, is higher in the good responders, and CBX7 high CML patients achieve faster a complete hematopoietic response than the CBX7 low CML patients [31]. This evidence concerns the gene CBX7 and chronic myelogenous leukemia, BCR-ABL1 positive.